Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOG-0279: Gemcitabine and Cisplatin with IMRT for Vulvar Cancer
NCT01595061Phase 2
Key facts
- Status
- Unknown
- Start
- Jul 2012
- Primary completion
- Sep 2020
- Countries
- 1
- Sponsor
- GOG Foundation
- Modality
- Nanoparticles, Small Molecules
- Conditions
- vulvar squamous cell carcinoma (VSCC)
01
Overview
Phase 2, open-label trial of gemcitabine and Cisplatin micelle injection (HA132) in vulvar squamous cell carcinoma (VSCC), sponsored by GOG Foundation. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Registry description
This phase II trial studies how well radiation therapy works when given with gemcitabine hydrochloride and cisplatin work in treating patients with squamous cell cancer of the vulva that has spread from where it started to nearby tissue or lymph nodes. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from…
Beyond the preview
Go deeper on NCT01595061.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01595061.